EPDS Postnatal Depression Scale

What the EPDS measures

The Edinburgh Postnatal Depression Scale (EPDS), developed by Cox and colleagues and published in the British Journal of Psychiatry in 1987, is the most widely used screening tool for perinatal depression. It consists of 10 questions about feelings over the past 7 days. Unlike general depression screeners, the EPDS was specifically designed for the perinatal period and does not include somatic symptoms (fatigue, sleep changes, appetite changes) that are normal in pregnancy and postpartum. This makes it more specific to depression during this life stage.

Valid for both antenatal and postnatal depression

Despite the name "postnatal," the EPDS is validated for both antenatal (during pregnancy) and postnatal (after birth) depression. Depression affects approximately 7-13% of women during pregnancy and 10-15% in the postpartum period. The EPDS is recommended by the American College of Obstetricians and Gynecologists (ACOG), the UK National Institute for Health and Care Excellence (NICE), and the World Health Organization for routine perinatal screening.

Score interpretation

The EPDS is scored 0-30. Scores <10 suggest depression is unlikely. Scores of 10-12 indicate possible depression, further assessment is warranted. Scores ≥13 indicate probable major depression (sensitivity ~86%, specificity ~78% in the original validation). Some guidelines use a cutoff of 12 or 13; the choice depends on the setting and whether sensitivity or specificity is prioritized. A lower cutoff (10) catches more cases but produces more false positives; a higher cutoff (13) is more specific.

The critical item 10

Question 10 asks about thoughts of self-harm. Any response other than "Never" (a score of 1, 2, or 3) requires immediate clinical follow-up, regardless of the total EPDS score. A woman may score low overall but still have significant suicidal ideation that warrants urgent assessment. In the United States, the 988 Suicide & Crisis Lifeline is available 24/7. Postpartum women with thoughts of harming themselves or their baby need immediate evaluation by a mental health professional.

Perinatal depression is common and treatable

Perinatal depression affects 1 in 7 women, it is the most common complication of pregnancy and childbirth. Despite its prevalence, it remains underdiagnosed and undertreated. Barriers include stigma, lack of screening, and confusion between normal postpartum adjustment ("baby blues") and clinical depression. The "baby blues" affect 50-80% of women, peak at 3-5 days postpartum, and resolve within 2 weeks. Symptoms lasting beyond 2 weeks, or symptoms severe enough to interfere with daily function, suggest postpartum depression and warrant treatment.

Treatment options

Perinatal depression is highly treatable. First-line treatments include:

• Psychotherapy: Cognitive Behavioral Therapy (CBT) and Interpersonal Therapy (IPT) are both effective. Many therapists specialize in perinatal mental health.
• Medication: Several SSRIs (sertraline, paroxetine, fluoxetine) are considered safe in pregnancy and breastfeeding. The benefits of treating maternal depression generally outweigh the risks of medication exposure.
• Support groups: Connecting with other mothers experiencing similar challenges can be powerfully therapeutic.
• Lifestyle: Sleep optimization (sleep when the baby sleeps), regular exercise (even walking), adequate nutrition, and social support all help.

If you are struggling, please reach out to your healthcare provider. You are not alone, and help is available.